NuGene International Inc. to Develop Groundbreaking Wound Treatment Combining Electrical Stimulation With Stem Cell Media

IRVINE, CA--(Marketwired - Jul 27, 2015) - NuGene International, Inc. ("NuGene") (OTCQB: NUGN), a developer, manufacturer and marketer of advanced skin and hair care lines utilizing adipose derived human stem cells and stem cell media, is preparing to introduce innovative new wound treatments that for the first time combines the healing qualities of micro-current stimulation with the rejuvenating properties of stem cell media.

According to the National Institute of Health, the epidermis (skin tissue) maintains a "skin battery" that generates an electric field and current flow when wounded. In certain experiments, a number of models demonstrated that a majority of the cell types within the wound can sense an electric field in the range of that internally generated in the wound and respond with a variety of biological and functional responses that can contribute to healing.

NuGene plans to utilize existing technology that introduces similar electrical micro-currents to wound areas to enhance skin healing by promoting cell migration and regeneration of skin tissue. The addition of NuGene's stem cell media is intended to be a complement to the electrical stimulus, providing an optimal environment for healing.

The product will be developed under the NuGene Biopharmaceuticals, Inc. ("BioPharma") subsidiary. BioPharma previously announced the acquisition of SkinGuardian®, an FDA-permitted (monographed) skin protectant, antiseptic, and moisturizing topical cream. SkinGuardian provides an antimicrobial composition that may be used against a wide variety of microorganisms including bacteria, fungi, prions and viruses. It serves as an effective guard for damaged and/or undamaged skin, and as an effective guard against infections.

"We believe that we have the opportunity to create a new standard of care for the treatment of wounds and certain medical conditions," stated Ali Kharazmi, CEO of NuGene. "We will continue to direct our research team to identify and develop new ways to utilize our proprietary stem cell technologies."

About NuGene, Inc.
NuGene International, Inc. specializes in developing, manufacturing and marketing proprietary regenerative cosmeceutical and pharmaceutical products based on adipose derived human stem cell and human stem cell media. The US Department of Health and Human Services calls regenerative medicine the "next evolution of medical treatments." The regenerative medical market which includes cosmeceuticals and pharmaceuticals was estimated at $7.2 Billion in the US in 2014 and is expected to rapidly grow in the coming years according to RNCOS Business Consultancy Services Global Cosmeceuticals Market report. NuGene's cosmeceutical and pharmaceutical products are based on proprietary stem cell based regenerative formulations derived from non-controversial, adult human stem cell derived media obtained from adipose tissue. NuGene's exclusive products combine its in-house advancements, proprietary technologies, and patent pending formulations. The company has four patents pending covering 15 unique applications. NuGene's goal is to leverage its knowledge and expertise to develop age defying cosmeceutical skincare and hair care products in addition to pharmaceutical products based on the same regenerative science platform.

Forward Looking Statements
This document contains "forward-looking statements," statements related to future, not past, events. In this context, forward-looking statements often address NuGene's expected future business and financial performance and financial condition, and often contain words such as "expect," "anticipate," "intend," "plan," "believe," "seek," "see," "will," "would," or "target." Forward-looking statements by their nature address matters that are, to different degrees, uncertain, such as statements about our current and future sales, planned operations, marketing activities and other operational, sales and financial plans. These may include our ability to convert pre-order commitments/wins into orders; timing of planned and anticipated product deliveries; the price we realize on orders since commitments/wins are stated at list prices; customer actions or developments such as customer returns and other factors that may affect the level of demand and performance of the major industries and customers we serve; the impact of regulation and regulatory, investigative and legal proceedings and legal compliance risks, including the impact of regulation and litigation; adverse market conditions, timing of and ability to obtain required regulatory approvals, or other factors relating to us; the impact of potential information technology or data security breaches; and the other factors that are described in "Risk Factors" in NuGene's Annual Report on Form 10-K for the year ended December 31, 2014. These or other uncertainties may cause our actual future results to be materially different than those expressed in our forward-looking statements. We do not undertake to update our forward-looking statements. This document also contains non-GAAP financial information. Management uses this information in its internal analysis of results and believes that this information may be informative to investors in gauging the quality of our financial performance, identifying trends in our results and providing meaningful period-to-period comparisons.